We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Thalassemia is a genetic blood disorder that affects hemoglobin production, leading to anemia and requiring regular blood transfusions. Myelodysplastic syndromes (MDS) are a group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to low blood counts and increased risk of leukemia.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
